Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expenses	$ 336	$ 11,448	$ 5,878	$ 19,506
General and administrative expenses	2,941	9,748	5,933	13,607
Total operating expenses	3,277	21,196	11,811	33,113
Other (income) expenses:
Other (income) expense, net	(197)	41	(321)	22
Loss before income tax benefit	(3,080)	(21,237)	(11,490)	(33,135)
Income tax benefit	0	0	(4)	(28)
Net loss	$ (3,080)	$ (21,237)	$ (11,486)	$ (33,107)
Net loss per share of common stock — basic (in dollars per share)	$ (0.04)	$ (0.29)	$ (0.16)	$ (0.45)
Net loss per share of common stock — diluted (in dollars per share)	$ (0.04)	$ (0.29)	$ (0.16)	$ (0.45)
Weighted-average shares of common stock outstanding — basic (in shares)	73,975,196	72,941,507	73,870,818	72,901,906
Weighted-average shares of common stock outstanding — diluted (in shares)	73,975,196	72,941,507	73,870,818	72,901,906